Gilead Sciences CEO to step down after nearly 3 decades

Biopharmaceutical company Gilead Sciences' President and CEO John F. Milligan, PhD, is stepping down by 2019, the company said July 25.

Dr. Milligan spent 28 years with Gilead. He will also step down from the board of directors by the end of 2018.

"It has been an honor to work at Gilead for my entire professional career and, now that the company is on solid footing for the future, the board and I have agreed it is a good time to turn the reins over to a new leader," Dr. Milligan said in a prepared statement. "I'm looking forward to a well-deserved break and will then move on to new and different opportunities."

The board is conducting a search for Dr. Milligan's successor.

More articles on business:
Microsoft expands rural broadband initiative with new partnership
Sergio Marchionne, architect of Fiat Chrysler turnaround , dead at 66
Top Amazon Studios executive departs

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars